Colonic cancers with a serrated morphology have been proposed to comprise a molecularly distinct tumor entity following an alternative pathway of genetic alterations independently of APC mutations. We demonstrate that intestinal epithelial cell specific expression of oncogenic K-ras G12D in mice induces serrated hyperplasia, which is characterized by p16 ink4a overexpression and induction of senescence. Deletion of Ink4a/Arf in K-ras G12D expressing mice prevents senescence and leads to invasive, metastasizing carcinomas with morphological and molecular alterations comparable to human KRAS mutated serrated tumors. Thus, we suggest that oncogenic K-ras represents a key player during an alternative, serrated pathway to colorectal cancer and hence propose RAS-RAF-MEK signaling apart from APC as an additional gatekeeper in colorectal tumor development.
INTRODUCTION
Despite significant improvements in prevention, colorectal cancer remains the third most common cancer as well as the third leading cause of cancer-associated death worldwide (Jemal et al., 2009; Kamangar et al., 2006 ). An exact understanding of the molecular events during carcinogenesis is crucial to develop efficient preventive and therapeutic strategies. The discovery of the genetic basis for familial adenomatous polyposis (FAP), the demonstration that genetic alterations of adenomatous polyposis coli (APC) are found in the majority of sporadic colorectal neoplasms (Vogelstein et al., 1988) , and the fact that loss of APC is sufficient to induce tumorigenesis led to the definition of APC as the ''gatekeeper'' of colonic carcinogenesis (Kinzler and Vogelstein, 1996) . APC mutations lead to chromosomal instability (CIN) and followed by additional mutations in tumor suppressors and oncogenes along the adenoma-carcinoma sequence ultimately to invasive cancer (Lengauer et al., 1998) .
However, accumulating evidence suggests that certain colorectal tumors do not follow this classical pathway and may arise independently of APC mutations. Because of their distinct histological and molecular features this group of tumors, which may explain 7.5% of all and 17.5% of proximal colorectal cancers, has been proposed to follow an alternative pathway, the so-called serrated route to cancer (Jass, 2007; Makinen, 2007; Noffsinger, 2009 ). This class of tumors comprises a morphologically and presumably molecularly heterogenous group ranging from hyperplastic polyps (HP), sessile serrated polyps (SSA), traditional serrated adenomas (TSA), and mixed polyps to serrated carcinoma (Noffsinger, 2009) , that all have a sawtooth-like (serrated) infolding of the neoplastic epithelium in common (Makinen, 2007) . Further typical characteristics of serrated carcinomas are mucin secretion, absence of ''dirty necrosis,'' lymphocytic infiltration and poor differentiation (Huang et al., 2004; Jass et al., 2002) . Because a very large number of activating mutations of either KRAS or BRAF have been detected as the earliest genetic alterations in serrated lesions, activation of the RAS-RAF-MEK-ERK-MAP axis has been suggested to be the initiating event in serrated carcinogenesis. In contrast to classical colonic tumors that show CIN,
Significance
Initiation of serrated tumors that follow the so-called alternative route to colorectal cancer is presumably caused by KRAS or BRAF mutations. We present a mouse model that develops colonic tumors that morphologically and molecularly mimics human serrated tumors harboring KRAS mutations. Thus, we provide what we believe to be an important tool for diagnostic and therapeutic studies of serrated cancers and highlight a so far unanticipated relevance of oncogene-induced senescence and Ink4a/Arf in colon cancer progression. serrated cancers are frequently characterized by a CpG island methylator phenotype (CIMP) and subsequent high-level DNA microsatellite instability (MSI-H) especially when located proximally and associated with BRAF mutations (Cunningham and Riddell, 2006) . However, KRAS mutated tumors are more frequently CIMP negative and MSI-L/MSS. A further mechanism proposed to play a key role in the pathogenesis of these tumors seems to comprise loss of the DNA mismatch repair gene hMLH1 or the DNA repair gene O 6 -methylguanine DNA methyltransferase (MGMT) (Jass et al., 2002) . Furthermore, it has been speculated that senescence might occur in early tumor stages preventing tumor progression (Jass, 2007) , however, functional evidence for this hypothesis is lacking. To test whether we could recapitulate development of serrated tumorigenesis in mice and to analyze the molecular events required for progression to cancer, we examined animals expressing oncogenic K-ras G12D specifically in enterocytes.
RESULTS

Enterocyte-Specific Expression of K-ras
G12D
Leads to Formation of Colonic Serrated Lesions
To establish whether intestinal epithelial cell (IEC)-specific expression of oncogenic K-ras G12D would allow serrated tumor formation, we crossed villin-Cre mice (Madison et al., 2002) to LSL-K-ras G12D/+ mice (Jackson et al., 2001) . The resulting mice, termed K-ras G12Dint , were born at the expected Mendelian ratio and did not display any overt developmental defects or weight differences (data not shown). Macroscopic analysis of K-ras G12D expressing intestines at 16 weeks of age displayed a significant elongation of their large intestine ( Figure 1A ). In contrast to LSL-K-ras G12D/+ control animals, whole mount analysis of methylene-blue stained colon from K-ras G12Dint mice revealed irregular crypt morphology (Figures 1B and 1C) . Histological analysis of K-ras G12Dint mice demonstrated occurrence of pronounced proximal colonic folds ( Figures 1D and 1E ). More importantly, in K-ras G12Dint colons we detected the expected serrated, hyperplastic transformation ( Figures 1F and 1G ), which was not patchy, but rather uniformly spread along the whole large intestine affecting nearly every single crypt. These hyperplastic crypts closely resembled the histology found in human premalignant lesions of the serrated route (see Figure S1 available online) and we therefore refer to this histology as ''murine serrated hyperplasia'' (mSH). Development of mSH occurred with a 100% penetrance and independently of gender or genetic background (C57BL/6;129 or after backcrossing to FVB/N for four generations). Despite the marked hyperplasia in K-ras G12Dint mice (defined by a significantly increased cell number/100 mm muscularis mucosae, Figure 1H ), we could not observe a difference in the colonic mitotic index determined by BrdU-labeling compared to littermate control mice ( Figure 1I ), or in apoptotic index examined by staining for active caspase 3 (data not shown).
In small intestine (SI) of K-ras G12Dint mice length was significantly increased along the longitudinal as well as the vertical axis ( Figure S2 ). In contrast to the colon of these mice, however, villus elongation was associated with a higher proliferation and migration rate determined by BrdU incorporation ( Figure S2 ). Further histological analysis of mutant SI revealed a high incidence of villus branching and consistent with elongation along the longitudinal axis, we frequently observed crypt fission ( Figure S2 ).
To test whether endogenous expression of K-ras G12D was sufficient to promote colonic tumor growth along the serrated route we monitored K-ras G12Dint up to 17 months. However, in none of the K-ras G12Dint expressing colons, progression of the mSH into more advanced tumor stages or carcinomas was observed. In contrast, but consistent with a hyperproliferative phenotype in the small intestine, 25% of K-ras G12Dint animals (7/28) developed a single adenoma in the duodenum/jejunum after 1 year ( Figure S2 and Table S1 ). Collectively, the endogenous expression of oncogenic K-ras led to significant albeit distinct alterations in the architecture of (black bars) mice. All animals were analyzed at the age of 16 weeks. Data are mean ± SE; n R 5; **p < 0.01 and not significant (n.s.) by t test. See also Figure S1 .
both small and large intestine. Whereas in small intestinal IEC K-ras G12D induced a persistent hyperproliferation and occasionally development of adenomas, mutant colon was characterized by the initiation of a presumably growth-arrested, serrated hyperplasia, which, however, did not progress into malignant tumors.
Oncogene-Induced Senescence Is Responsible for Growth Arrest of Colonic mSH Oncogene-induced senescence (OIS) is a form of stable growth arrest that can be induced by overexpression of oncogenes in cultured cells (Collado and Serrano, 2010) . OIS can occur in vivo in various premalignant lesions of malignant melanoma, lymphoma, prostate, and lung cancer presumably having a tumor suppressive function (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005) . Oncogenic K-ras mediated Erk activation is one of the main inducers of senescence (Mooi and Peeper, 2006) , which might be the underlying cause for the block of progression in mSH. To test this, we isolated IEC for biochemical analysis. First, activation of K-ras in mutant IEC was confirmed by pull-down assay of GTP-bound Ras ( Figure 2A ). This led to the expected phosphorylation of Erk1/2 without affecting total protein levels of Erk ( Figure 2B ). In contrast, activation of other downstream effectors of Ras, such as Akt and Ral (Malumbres and Barbacid, 2003) remained either unchanged or undetectable in colonocytes of mice of either genotype, respectively ( Figures 2C and 2D ). Furthermore, we did not observe any activation of the other MAP-kinases p38 or JNK ( Figures 2E and 2F ), which had been found to be upregulated in K-ras G12D expressing lungs (Lee et al., 2002) , indicating that endogenous expression of K-ras G12D in IEC primarily activates Erk1/2. To test, whether K-ras mediated Erk-activation might lead to senescence, we examined enzymatic activity of senescence-associated (SA) b-galactosidase, a marker indicating senescence both in vitro and in vivo (Dimri et al., 1995) , in colons of K-ras G12Dint mice and littermates. As hypothesized, mSH exhibited strikingly elevated SA-b-galactosidase activity, which was not observed in untransformed colons of control littermates (Figures 2G and 2H) . The presence of OIS was further supported by upregulation of mRNA encoding the senescence marker Dec1 ( Figure 2I ) as well as increased p16 ink4a mRNA and protein levels in isolated colonic IEC of K-ras G12Dint mice ( Figures 2I and 2J ).
However, we could not detect upregulation of p19 Arf or p53 mRNA ( Figure 2I ) or protein levels ( Figure 2J and data not shown).
In contrast, analysis of small intestinal IEC displayed also selective phosphorylation of Erk, but in line with the observed hyperproliferation in K-ras G12D expressing SI, neither upregulation of p16 ink4a mRNA nor induction of senescence were observed ( Figure S2 ). Unlike our mouse model that exhibits oncogenic K-ras starting from embryonic day 12.5 dpc (Madison et al., 2002) , tumor-initiating mutations in human colon occur during adulthood. To confirm that activation of oncogenic Kras in murine adult IEC could still induce serrated hyperplasia, we crossed LSL-K-ras G12D to inducible villin-creER T2 /LSL-K-ras G12D/+ mice (el Marjou et al., 2004 
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Oncogenic K-Ras in Serrated Colon Tumorigenesis deficient mice (Serrano et al., 1996) to generate K-ras G12Dint / Ink4a/Arf À/À (resulting in IEC-specific activation of K-ras
G12D
and whole body deletion of Ink4a/Arf). Consistent with the upregulation of p16 ink4a in colonic but not small intestinal K-ras
G12Dint
IEC, deletion of Ink4a/Arf induced colonic hyperproliferation ( Figure 3A ), but left small intestinal morphology of K-ras G12Dint mice unaffected. Furthermore, elongation of colonic proximal folds was more pronounced on Ink4a/Arf-loss than in K-ras G12Dint mice ( Figure 3B , compare to Figure 1E ). More importantly, within 12 weeks, in more than 50% of K-ras G12Dint /Ink4a/ Arf À/À mice (17/32), hyperplasia had progressed into tumors that resembled traditional serrated adenomas ( Figure 3C and Figure S3 ) that were located exclusively in the proximal colon (Table S1 ). Loss of Ink4a/Arf-mediated senescence in murine serrated adenomas was confirmed by the lack of SA-b-gal activity ( Figure 3D ). Proliferating cells, determined by BrdU incorporation, were predominantly located in the lower half of crypts ( Figure 3E ). Further immunohistochemical analysis of these adenomas in K-ras G12Dint /Ink4a/Arf À/À mice revealed aberrant expression of MUC5AC ( Figure 3F ), suggesting differentiation of mucous cells toward gastric surface mucous cells. Moreover, we detected significant lymphocytic infiltration along the lamina propria and surrounding the adenomatous epithelia determined by immunofluorescent staining against CD3 and CD45 (Figures 3G and 3H) . While epithelial cells stained positive for cyclin D1 ( Figure 3I ), b-catenin showed a membrane bound expression pattern ( Figure 3J ) and these cells retained APC expression (data not shown). Only few cells expressed nuclear c-myc (Figure 3K) , collectively indicating that these tumors did not show activation of the Wnt pathway. Remarkably, within 12 weeks in 76% of the K-ras G12Dint /Ink4a/Arf À/À mice (13/17) with serrated adenomas, tumors had developed into fully invasive adenocarcinomas (Figures 4A-4C and Figure S4 ). These cancers were exclusively located in the proximal colon and displayed a highly proliferative and poorly differentiated phenotype (Figure 4D) . Expression of cytokeratin (CK) 8/18 confirmed the epithelial origin of these invasive cells ( Figure 4E) . Surprisingly, expression of p53 was consistently positive in all colonic serrated cancers ( Figure 4F ), however, we were not able to detect any mutations when we sequenced exons 5-8 of Tp53 in laser-microdissected tumor DNA. In agreement with a membranous expression of b-catenin, we also did not detect any mutations in exon 3 of b-catenin that could lead to stabilization of b-catenin. More importantly, 62% of these invasive cancers (8/13) had metastasized to the lung ( Figure 4G and Table S1 ). Intestinal origin of these metastases was confirmed by staining for CK 20 ( Figure 4H) . Notably, by 12 weeks the majority of K-ras
mice became moribund showing signs of severe respiratory distress. We therefore analyzed lungs of these animals and detected also lung tumors in mice that did not have invasive serrated cancer suggesting the existence of primary lung adenomas. This was confirmed by positive immunohistochemical staining for TTF-1, a marker, which is specifically expressed in primary lung tumors, but not in colonic metastases and negative staining for CK7 ( Figure S4 ). Recombination of the mutated K-ras allele in primary lung adenomas was confirmed by PCR analysis of DNA isolated from laser-capture microdissected tumor tissue (data not shown). The early occurrence of primary lung tumors limited a longer monitoring of K-ras
To functionally examine the role of p53 in serrated tumor development, we crossed K-ras G12Dint animals to conditional Figure S3 and Table S1 .
Trp53 mice (Jonkers et al., 2001) tumors were indeed CIMP-negative. To assess whether murine serrated cancers displayed MSI, we compared DNA from microdissected tumors to DNA isolated from tumor-free livers of the same animals using a panel of five microsatellite repeat markers faithfully detecting MSI (Kabbarah et al., 2003) . The majority of tumors was either MSI-L (4/10) or 
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Oncogenic K-Ras in Serrated Colon Tumorigenesis MSS (5/10) and only 1 of 10 analyzed tumors (no. 18161) fulfilled the criteria for MSI-H (Boland et al., 1998) (Figure 4J) . Collectively, these data demonstrated that the murine K-ras mutated cancers were CIMP-negative and MSS-L/MSS, thus closely resembling the molecular characteristics of human KRAS mutated serrated polyps and carcinomas. -methyl-guanine-adducts and is commonly used in animal models to induce classical colonic tumors (Boivin et al., 2003) . AOM is known to initiate mutations in exon 3 of Ctnnb, thereby stabilizing b-catenin and subsequently activating Wnt signaling (Greten et al., 2004) . Because AOM primarily induces colonic tumors we preferred this model to genetic models of sporadic tumorigenesis, such as Apc mutants, which primarily develop small intestinal tumors. Sixteen weeks after the first AOM injection animals were sacrificed and tumor incidence as well as tumor morphology was determined. In contrast to the serrated cancers that developed in K-ras G12Dint /Ink4a/Arf À/À mice, all of the AOMinduced adenomas were located in the distal colon, which is the typical location of tumors following the classical pathway. However, K-ras G12Dint mice developed $13-fold more tumors compared to control littermates ( Figure 5A ) in agreement with the notion that oncogenic K-ras enhances classical colon cancer progression (Haigis et al., 2008; Janssen et al., 2006) . The vast majority of AOM-induced tumors were tubular and well-differentiated, displayed low to moderate dysplasia and none of them was invasive ( Figures 5B and 5C ). Figure 5H ). When we performed gene set enrichment analysis (GSEA) to compare these gene expression profiles to that of mice with an IEC-restricted deletion of Apc (Sansom et al., 2007) , the AOM-induced tumors but not the serrated tumors demonstrated a high enrichment with the ''Wnt signature'' that is reminiscent of classical tumors ( Figure 5I ) (Kaiser et al., 2007) .
Recently, a gene expression profiling study demonstrated that human serrated cancers comprise a distinct molecular subclass of colon cancers and several specific biomarkers were identified (Laiho et al., 2007) . When comparing serrated cancers to conventional colon cancers it was suggested that upregulation of HIF1a and its downstream target BNIP3L as well as downregulation of EPHB2 and PTCH could be specifically found in serrated cancers. Although it is not clear whether the serrated cancers in this study contained KRAS or BRAF mutations, we compared RNA expression levels of these biomarkers in murine AOM-induced tumors and serrated cancers. Similarly to human cancers, RNA levels coding for EphB2 were higher in classical AOM-induced tumors whereas Hif-1a and Bnip3l mRNAs were markedly upregulated in murine serrated cancers, yet expression of Ptch remained unchanged ( Figure 5J and data not shown). Immunohistochemical analysis confirmed the reciprocal expression pattern of EphB2 and Hif-1a in tumor epithelium of classical and serrated tumors ( Figures 5K-5N ).
Human KRAS Mutated Serrated Adenomas Show OIS and Express High Levels of p16
INK4A
Having established the importance of OIS and Ink4a/Arf in murine serrated tumor development, we wanted to examine whether senescence and p16
INK4A upregulation might be observed in human KRAS associated serrated carcinogenesis as well. Therefore, we obtained during routine colonoscopy 18 hyperplastic polyps (HP), of which four contained a KRAS (codon 12) mutation and as hypothesized, three of them revealed a marked positive expression of SA-b-gal indicating OIS in HP ( Figure 6A ). Furthermore, this was accompanied by p16 INK4A expression, which was undetectable in unaffected, healthy mucosa ( Figures 6C and 6D ). To examine whether p16
upregulation was a general phenomenon commonly found in KRAS mutated benign serrated lesions and whether tumor progression was associated with loss of p16 INK4A , we extended our analysis to a cohort of 93 serrated tumors comprising hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas, early invasive serrated adenocarcinomas within a serrated adenoma and also advanced serrated adenocarcinomas with metastasis. We screened this cohort for the presence of KRAS (codon 12, 13) or BRAF (V600E) mutations and identified 13 serrated tumors that contained mutated KRAS (Table 1) . Independently of tumor stage and grade of intraepithelial neoplasia (dysplasia) all 13 KRAS mutated tumors were MSS, expressed MLH1 and except two cases displayed membranous b-catenin expression indicating normal Wnt signaling (Table 1) . In nearly all samples we could detect robust expression of p16
INK4A that increased with degree of intraepithelial neoplasia (dysplasia), whereas p14 ARF was not expressed (Figures 7A-7D ). However, in three of four tumors that showed signs of invasion p16 INK4A expression was selectively reduced at the infiltrative front of invasion and correlated inversely with expression of the proliferation marker Ki67 (Figures 7E and 7F) . In one advanced adenocarcinoma with metastasis, p16
INK4A expression was completely lost. Decreased expression or loss of p16 INK4A was in most cases associated with CDKN2A promoter methylation. Because we had observed nuclear accumulation of p53 in murine advanced serrated tumors, we wanted to examine whether we could recapitulate this unexpected finding in human samples as well. Intriguingly, in almost all invasive cancers we found nuclear accumulation of p53. Although in various cancers
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Oncogenic K-Ras in Serrated Colon Tumorigenesis increased nuclear p53 accumulation is frequently caused by TP53 mutations (Greenblatt et al., 1994) , we could not detect any mutations in the most commonly affected exons 5-8 of TP53, resembling the situation in murine serrated cancers.
DISCUSSION
The majority of nonhereditary colorectal cancers follow a welldefined tumor progression model involving APC mutation as an initiating event. Mutation of K-ras occurs at later stages and is supposedly not sufficient to initiate classical colonic tumorigenesis per se. We provide what we believe to be genetic evidence that enterocyte specific expression of oncogenic K-ras in mice can induce widespread colonic lesions that morphologically resemble benign human serrated polyps. Our results therefore support the hypothesis that indeed activation of the RAS-RAF-MEK-ERK cascade may be the initiating event in human serrated colorectal tumors. Oncogene induced senescence has been suggested to have a tumor suppressive function in a variety of different tumors (Collado and Serrano, 2010) . Although neither in primary human colonic tissue nor in experimental models of colorectal cancer senescence has been confirmed yet, OIS may provide a potential molecular mechanism explaining the rare progression of benign early, serrated lesions toward serrated adenocarcinoma. Indeed, we provide evidence that OIS developed in both hyperplastic mutant mouse tissue as well as in human serrated polyps and this was paralleled by upregulation of p16. Similarly to tumor progression in mice that was dependent on loss of Ink4a/Arf, p16 INK4A expression was either completely absent or lost at the infiltrating front of invasion in the majority of human invasive carcinomas. Furthermore, in tumors that did not express or displayed a reduced p16 INK4A expression, CDKN2A promoter methylation was commonly confirmed. Although we cannot rule out that loss of Ink4a/Arf in stromal cells might affect tumor progression in mice, in light of the findings in human tissues our data strongly support the concept that OIS and p16 upregulation confer tumor suppressive effects during serrated tumorigenesis and suggest that loss of Ink4a/Arf could be one key mechanism required to overcome growth arrest in mutated cells. Because only $50% of K-ras G12Dint /Ink4a/Arf À/À mice developed adenomas and carcinomas, presumably additional genetic events are required for serrated tumor progression apart from Ink4a/Arf loss. Based on our results obtained with the AOM-model, which shifted the tumor type toward classical tumorigenesis, activation of Wnt signaling does not seem to play a major role in serrated cancer development. Accordingly APC or CTNNB mutations are found infrequently in human serrated polyps. However, one potentially important candidate could be Mgmt, which is often found inactivated in KRAS initiated serrated tumorigenesis (Jass, 2007) . Although in K-ras G12Dint mice Mgmt expression was retained at all stages, it will still be interesting to functionally examine the role of Mgmt as well as to identify other so far unknown genes involved in serrated tumor progression in these mice. The mouse model we describe very closely mimics human pathology and demonstrates many features of human serrated polyps, i.e., proximal location, aberrant expression of gastric mucous markers, lymphocytic infiltration and bottom-up morphogenesis (Jass et al., 2002) . Because serrated polyps comprise a morphologically and molecularly heterogenous group of tumors, we restricted our comparative analysis to human KRAS mutated serrated lesions. Intriguingly, in addition to the phenotypic similarities also the molecular alterations were strikingly similar between our mouse model and the human tumors. However, considering the fact that BRAF mutations Our results demonstrate a highly pronounced cell type specificity of oncogenic K-ras and unravel a clear difference between small and large intestinal function of K-ras. Small intestinal epithelial cells did not show OIS, Dec1, or p16 upregulation, but they were characterized by persistent hyperproliferation and the occurrence of sporadic tumors after 1 year. Consequently, no small intestinal tumors were observed on loss of Ink4a/Arf. In contrast, K-ras G12D expressing colon was characterized by development of OIS that presumably occurred after an initial brief period of hyperproliferation (compare proliferation rates in inducible villin-cre ERT2 /LSL-K-ras G12D/+ mice 6 days and 21 days after induction; Figure S3 ) and led to the formation of mSH, which did not progress unless Ink4a/Arf was deleted.
Although K-ras G12D selectively activates Erk in both SI and colon, OIS was induced only in colon, demonstrating the requirement for expression of so far unidentified coexisting factors other than Erk, that regulate senescence in the large intestine, but not in the small intestine. These data also raise the question how valid certain animals models are concerning colorectal tumor development, in case these models develop tumors only in small intestine.
To date no other genetic model addressing the function of oncogenic K-ras in the intestine has addressed the development of serrated tumorigenesis. Recent reports demonstrated the occurrence of colonic hyperplasia in mice expressing the same K-ras G12D mutant, however, serrated tumors or the existence of OIS were not described (Haigis et al., 2008; Trobridge et al., 2009) . Furthermore, other studies analyzing the function of intestinal K-ras made use of a transgenic approach (Janssen et al., 2006; Janssen et al., 2002) , which-albeit moderate overexpression levels of oncogenic K-ras-might lead to the activation of additional downstream signaling cascades. Moreover, when K-ras was activated using an endogenous K-ras V12 mutant, Cre-recombinase was expressed under the control of a promoter that is preferentially expressed in small intestine (Ireland et al., 2004; Sansom et al., 2006) , which could account for the different phenotypes regarding the colon. Nevertheless, concerning the K-ras mediated hyperproliferative phenotype in small intestine and in respect to concomitant activation of oncogenic K-ras along with Wnt signaling in either small or large intestine, our data are in agreement with other reports (Haigis et al., 2008; Janssen et al., 2006; Sansom et al., 2006 In summary, we provide evidence that oncogenic K-ras activation represents a key event during early Wnt-independent serrated tumorigenesis in mice and suggest that upregulation of p16 INK4A and induction of OIS is a common phenomenon in human KRAS mutated serrated tumor development. Thus, we propose that loss of p16 INK4A function for example by promoter methylation can be one possibility to overcome senescence thereby allowing tumor progression along the alternative, serrated route. Although there is no doubt anymore that benign serrated lesions can progress into malignant stages, it remains an important task to unravel useful markers that distinguish those polyps that are likely to progress to cancer. Our mouse model may represent an excellent tool to identify some of them. 
EXPERIMENTAL PROCEDURES Mice and Induction of Colonic Tumors
To express K-ras G12D in enterocytes, we crossed LSL-K-ras G12D (Hingorani et al., 2003) to villin-Cre mice (both on a C57BL/6;129 background) (Madison et al., 2002) . Ink4a/Arf null (FVB/N.129) (Serrano et al., 1996) were obtained from the MMHC, National Cancer Institute. K-ras G12Dint mice were backcrossed for four generations on a FVB background before they were intercrossed with Ink4a/Arf null mice. Activation of K-ras G12D in villin-cre ERT2 / LSL-K-ras G12D/+ mice was achieved by five daily oral administrations of 1 mg tamoxifen in an ethanol/sunflower oil mixture. Six-to eight-week-old mice (LSL-K-ras G12D and K-ras G12Dint ) were injected i.p. with 15 mg/kg AOM (NCI) once a week for 6 weeks. Sixteen weeks after the first injection animals were sacrificed, colons were removed and analyzed as described (Greten et al., 2004) . In all experiments littermate controls were used assuring comparison of mice on the same genetic background. All procedures conformed to the regulatory standards and were approved by the Regierung von Oberbayern. All human samples were obtained with the approval of the ethics committee of the Technical University of Munich from subjects that had given their written informed consent.
Determination of Proliferation and Migration Rates
Mice were injected i.p. with 100 mg/kg BrdU (Sigma) 1.5 hr before sacrifice and paraffin sections were stained using a-BrdU antibody (Amersham Bioscience RPN201). For determination of migration rates, BrdU-injected mice were sacrificed after 48 hr. For each analysis BrdU-positive cells were scored in 12 full crypts from two to five animals of each genotype.
MSI and Methylation Analysis
For examination of murine tissues PCR-based amplification of five microsatellite repeat markers (Kabbarah et al., 2003) was performed using DNA isolated from tumor tissue as well as healthy livers of the corresponding animals. For analysis of human tissue mononucleotide markers BAT25 and BAT26 were used (Deschoolmeester et al., 2008) . Fluorescent PCR products were analyzed by capillary electrophoresis using an ABI 3100 Genetic Analyzer (Applied Biosystems) and 3130 Data Collection v3.0 software. Methylated DNA immunoprecipitation and hybridization on a NimbleGen 385K MM8 RefSeq promoter array was performed by imaGenes (GmbH, Berlin).
Laser Capture Microdissection
Laser capture microdissection and sequencing analysis of exon 3 of Ctnnb and exons 5-8 of Tp53 were performed as described previously (Greten et al., 2004) .
Senescence Assay
Tissue was fixed in 4% paraformaldehyde for 2 hr on ice, washed twice with PBS, and kept in 15% sucrose solution for 4 hr followed by an overnight incubation in 30% sucrose at 4 C. Samples were embedded in OCT and shockfrozen. SA-b-galactosidase staining was performed on 6-mm cryosections using the Senescence b-galactosidase staining kit (Cell Signaling 9860) according to the manufacturer's instructions.
Protein Analysis
Isolation of enterocytes, immunoblot analysis, and immune complex kinase assay were essentially performed as described (Bollrath et al., 2009 ). Ras and Ral activation assays were performed using the Ras Activation Assay Kit (Upstate 17-218) or Ral Activation Assay kit (Upstate 17-300) according to the manufacturer's instructions. The following antibodies were used in immunoblot analysis: a-phospho-Erk (9101), a-phospho-p38 (9211), a-phospho-Akt (9271), a-Erk1/2 (9102), a-Akt (9272), a-p15 INK4b (4822, Cell Signaling), a-Jnk (PharMingen 554286), a-p38 (SC-535), a-p16 ink4a (SC-1661), a-p19 ARF (Abcam ab80-50), and a-b-actin (A4700, Sigma).
Immunohistochemistry
Paraffin sections (3.5 mm) were stained using standard immunohistochemical procedures. The following antibodies were used for murine tissues: a-cyclin D1 (Santa Cruz SC-718), a-c-myc (SC-788), a-b-catenin (UBI 6734), a-p53 (Novocastra CM5), a-cytokeratin8/18 (Progen GP11), a-cytokeratin 7 (Progen 16090), a-cytokeratin 20 (Progen GP-K20), a-thyroid transcription factor-1 (Dako M3575), a-EphB2 (R&D Systems, AF467), a-HIF1a (Novus, NB 100-131) a-CD45 (PharMingen 553089), a-CD3 (BD PharMingen 555274), and a-MUC5AC (Neomarker MS-145). Immunohistochemical analysis of human tissues was performed on a Benchmark XT (Ventana Medical Systems, Inc.) using the following antibodies: a-MLH1 (BD PharMingen 551091), a-MGMT (medac MS-470-P), a-b-catenin (Ventana 760-4242), a-p14 ARF (CytoMed Systems Mob456), a-p16 INK4A (Diagnostic Biosystems Mob213), and a-p53
(NeoMarkers MS-186-Po).
RNA Analysis
The RNeasy Mini Kit (QIAGEN) was used for RNA extraction of isolated enterocytes. Synthesis of cDNA was performed using SuperScript II Reverse Transcriptase (Invitrogen). Real-time PCR analysis using Power SYBR Green PCR Master Mix (Applied Biosystems) was performed on a StepOne Plus Real-Time PCR system (Applied Biosystems). Primer sequences are available on request. Gene expression profiling of tumor tissue was performed using Affymetrix Gene ST GeneChips as reported before (Eckmann et al., 2008) . In gene set enrichment analysis (GSEA) we matched 87 transcripts that were upregulated in Apc-deficient IEC (Sansom et al., 2007) to all transcripts from the Affymetrix Mouse Genome 430A 2.0 Array, respectively. GSEA software is provided by Broad Institute of MIT and Harvard University (http://www.broad.mit.edu/ gsea). We acknowledge the use of GSEA software (Subramanian et al., 2005) to validate correlation between molecular pathways signatures in any phenotype of interest. For analysis of gene sets we changed default parameters as follows: permutation number to 1000; collapse data set to gene symbols if ''false''; gene sets <1 and >2000 were excluded.
Statistical Analysis
Data are expressed as mean ± SEM. Differences were analyzed by unpaired, two-tailed Student's t test using Prism4 (GraphPad Software); p value % 0.05 were considered significant.
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